Loading
A phase 3 trial of Dexamethasone, Daratumumab, Bortezomib in multiple myeloma, run by Celgene, active and no longer recruiting.
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) is a phase 3 interventional study registered as NCT04975997 by Celgene, with 939 participants enrolled, started 2022-06-23 and due to reach its primary completion in 2027-11-16. Interventions recorded: Dexamethasone, Daratumumab, Bortezomib, Iberdomide, Iberdomide. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Iberdomide, Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib.
Shares Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Bortezomib, Dexamethasone.
Shares Cereblon E3 ligase modulators (CELMoDs), Antiemetics for chemotherapy-induced nausea and vomiting, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Antiemetics for chemotherapy-induced nausea and vomiting, Daratumumab, Dexamethasone, Relapsed or refractory multiple myeloma.
Shares Cereblon E3 ligase modulators (CELMoDs), Daratumumab, Bortezomib, Dexamethasone.